Mov Disord:帕金森患者,外周血的免疫特征如何?

2021-08-08 Freeman MedSci原创

与HCs相比,PD患者的外周免疫谱发生改变,NLR较高。

帕金森病(PD)是最常见的神经退行性疾病之一,但其发病机制仍不清楚。

目前的证据表明,神经炎症是帕金森病神经退行性疾病的病因和进展的一个主要因素。神经炎症不是对神经变性的简单反应,PD与中枢和外周的免疫反应都有关。

有证据表明,在PD中存在着脑-外周的相互作用,或者是通过胶质-淋巴途径,或者是通过血脑屏障的干扰。

据描述,与健康对照组(HCs)相比,PD患者的血液、脑脊液(CSF)和大脑中的促炎症细胞因子升高了。

在PD患者的外周血中,白细胞及其亚群的数量和质量都发生了变化。中性粒细胞与淋巴细胞比率(neutrophil-to-lymphocyte ratio,NLR)是一个公认的机体整体炎症状态的指标。

该比率整合了两种白细胞亚群和互补的免疫途径的信息:中性粒细胞与慢性炎症有关,而淋巴细胞可能代表调节途径。它已被用作癌症、血管和炎症性疾病的预后因素,以及阿尔茨海默病的认知障碍的标志物。有人认为NLR在PD中升高,作为外周炎症的生物标志物,但结果有争议。

藉此,西班牙Universitario Virgen del Rocío的Laura Muñoz-Delgado等人,探究了PD患者与HCs相比,是否存在促炎症的外周免疫状态。

他们首先通过病例对照研究探究了PD患者和HCs之间外周免疫状况的差异。

然后,探究了NLR是否与PD的临床特征有关。

最后,进行了荟萃分析以澄清NLR在PD中的作用。

他们发现:在病例对照研究中,PD患者的NLR明显高于HCs(2.47 ± 1.1 vs. 1.98 ± 0.91,P < 0.001)。

但没有发现NLR与发病年龄、疾病严重程度或疾病持续时间之间的关联。

荟萃分析显示,PD患者的NLR可能更高。

这个研究的重要意义在于发现了:与HCs相比,PD患者的外周免疫谱发生改变,NLR较高。


原文出处:
Peripheral Immune Profile and Neutrophil‐to‐Lymphocyte Ratio in Parkinson’s Disease. Mov Disord. Published online June 8, 2021:mds.28685. doi:10.1002/mds.28685

 
 
 
 

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (7)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1784450, encodeId=ef211e84450c9, content=<a href='/topic/show?id=a727600194' target=_blank style='color:#2F92EE;'>#Disord#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6001, encryptionId=a727600194, topicName=Disord)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aad0444, createdName=cmsvly, createdTime=Sat Oct 16 20:07:51 CST 2021, time=2021-10-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2013682, encodeId=2d2b2013682fa, content=<a href='/topic/show?id=7d69598468' target=_blank style='color:#2F92EE;'>#Dis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5984, encryptionId=7d69598468, topicName=Dis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Mon Nov 08 20:07:51 CST 2021, time=2021-11-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1309253, encodeId=640f1309253c1, content=<a href='/topic/show?id=8dbb29086c6' target=_blank style='color:#2F92EE;'>#免疫特征#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=29086, encryptionId=8dbb29086c6, topicName=免疫特征)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e080359, createdName=surilei, createdTime=Mon Aug 09 20:07:51 CST 2021, time=2021-08-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1578576, encodeId=113f15e85760d, content=<a href='/topic/show?id=fd724282021' target=_blank style='color:#2F92EE;'>#外周血#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42820, encryptionId=fd724282021, topicName=外周血)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a31916414168, createdName=ms3994565386320060, createdTime=Mon Aug 09 20:07:51 CST 2021, time=2021-08-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1006100, encodeId=f5451006100cb, content=有收获, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=05885564664, createdName=ms3000000120045871, createdTime=Sun Aug 08 19:06:08 CST 2021, time=2021-08-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1005989, encodeId=93111005989b1, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201210/017ce76ad1014a7ab78fda1719777146/e1909743852a42449a457ef64bb5bfe8.jpg, createdBy=26641794232, createdName=ms812711744394816, createdTime=Sun Aug 08 10:55:25 CST 2021, time=2021-08-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1005951, encodeId=b9c2100595128, content=顶, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1f685566957, createdName=jyq1990, createdTime=Sun Aug 08 08:42:41 CST 2021, time=2021-08-08, status=1, ipAttribution=)]
    2021-10-16 cmsvly
  2. [GetPortalCommentsPageByObjectIdResponse(id=1784450, encodeId=ef211e84450c9, content=<a href='/topic/show?id=a727600194' target=_blank style='color:#2F92EE;'>#Disord#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6001, encryptionId=a727600194, topicName=Disord)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aad0444, createdName=cmsvly, createdTime=Sat Oct 16 20:07:51 CST 2021, time=2021-10-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2013682, encodeId=2d2b2013682fa, content=<a href='/topic/show?id=7d69598468' target=_blank style='color:#2F92EE;'>#Dis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5984, encryptionId=7d69598468, topicName=Dis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Mon Nov 08 20:07:51 CST 2021, time=2021-11-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1309253, encodeId=640f1309253c1, content=<a href='/topic/show?id=8dbb29086c6' target=_blank style='color:#2F92EE;'>#免疫特征#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=29086, encryptionId=8dbb29086c6, topicName=免疫特征)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e080359, createdName=surilei, createdTime=Mon Aug 09 20:07:51 CST 2021, time=2021-08-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1578576, encodeId=113f15e85760d, content=<a href='/topic/show?id=fd724282021' target=_blank style='color:#2F92EE;'>#外周血#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42820, encryptionId=fd724282021, topicName=外周血)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a31916414168, createdName=ms3994565386320060, createdTime=Mon Aug 09 20:07:51 CST 2021, time=2021-08-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1006100, encodeId=f5451006100cb, content=有收获, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=05885564664, createdName=ms3000000120045871, createdTime=Sun Aug 08 19:06:08 CST 2021, time=2021-08-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1005989, encodeId=93111005989b1, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201210/017ce76ad1014a7ab78fda1719777146/e1909743852a42449a457ef64bb5bfe8.jpg, createdBy=26641794232, createdName=ms812711744394816, createdTime=Sun Aug 08 10:55:25 CST 2021, time=2021-08-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1005951, encodeId=b9c2100595128, content=顶, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1f685566957, createdName=jyq1990, createdTime=Sun Aug 08 08:42:41 CST 2021, time=2021-08-08, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1784450, encodeId=ef211e84450c9, content=<a href='/topic/show?id=a727600194' target=_blank style='color:#2F92EE;'>#Disord#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6001, encryptionId=a727600194, topicName=Disord)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aad0444, createdName=cmsvly, createdTime=Sat Oct 16 20:07:51 CST 2021, time=2021-10-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2013682, encodeId=2d2b2013682fa, content=<a href='/topic/show?id=7d69598468' target=_blank style='color:#2F92EE;'>#Dis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5984, encryptionId=7d69598468, topicName=Dis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Mon Nov 08 20:07:51 CST 2021, time=2021-11-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1309253, encodeId=640f1309253c1, content=<a href='/topic/show?id=8dbb29086c6' target=_blank style='color:#2F92EE;'>#免疫特征#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=29086, encryptionId=8dbb29086c6, topicName=免疫特征)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e080359, createdName=surilei, createdTime=Mon Aug 09 20:07:51 CST 2021, time=2021-08-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1578576, encodeId=113f15e85760d, content=<a href='/topic/show?id=fd724282021' target=_blank style='color:#2F92EE;'>#外周血#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42820, encryptionId=fd724282021, topicName=外周血)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a31916414168, createdName=ms3994565386320060, createdTime=Mon Aug 09 20:07:51 CST 2021, time=2021-08-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1006100, encodeId=f5451006100cb, content=有收获, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=05885564664, createdName=ms3000000120045871, createdTime=Sun Aug 08 19:06:08 CST 2021, time=2021-08-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1005989, encodeId=93111005989b1, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201210/017ce76ad1014a7ab78fda1719777146/e1909743852a42449a457ef64bb5bfe8.jpg, createdBy=26641794232, createdName=ms812711744394816, createdTime=Sun Aug 08 10:55:25 CST 2021, time=2021-08-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1005951, encodeId=b9c2100595128, content=顶, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1f685566957, createdName=jyq1990, createdTime=Sun Aug 08 08:42:41 CST 2021, time=2021-08-08, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1784450, encodeId=ef211e84450c9, content=<a href='/topic/show?id=a727600194' target=_blank style='color:#2F92EE;'>#Disord#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6001, encryptionId=a727600194, topicName=Disord)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aad0444, createdName=cmsvly, createdTime=Sat Oct 16 20:07:51 CST 2021, time=2021-10-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2013682, encodeId=2d2b2013682fa, content=<a href='/topic/show?id=7d69598468' target=_blank style='color:#2F92EE;'>#Dis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5984, encryptionId=7d69598468, topicName=Dis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Mon Nov 08 20:07:51 CST 2021, time=2021-11-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1309253, encodeId=640f1309253c1, content=<a href='/topic/show?id=8dbb29086c6' target=_blank style='color:#2F92EE;'>#免疫特征#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=29086, encryptionId=8dbb29086c6, topicName=免疫特征)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e080359, createdName=surilei, createdTime=Mon Aug 09 20:07:51 CST 2021, time=2021-08-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1578576, encodeId=113f15e85760d, content=<a href='/topic/show?id=fd724282021' target=_blank style='color:#2F92EE;'>#外周血#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42820, encryptionId=fd724282021, topicName=外周血)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a31916414168, createdName=ms3994565386320060, createdTime=Mon Aug 09 20:07:51 CST 2021, time=2021-08-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1006100, encodeId=f5451006100cb, content=有收获, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=05885564664, createdName=ms3000000120045871, createdTime=Sun Aug 08 19:06:08 CST 2021, time=2021-08-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1005989, encodeId=93111005989b1, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201210/017ce76ad1014a7ab78fda1719777146/e1909743852a42449a457ef64bb5bfe8.jpg, createdBy=26641794232, createdName=ms812711744394816, createdTime=Sun Aug 08 10:55:25 CST 2021, time=2021-08-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1005951, encodeId=b9c2100595128, content=顶, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1f685566957, createdName=jyq1990, createdTime=Sun Aug 08 08:42:41 CST 2021, time=2021-08-08, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1784450, encodeId=ef211e84450c9, content=<a href='/topic/show?id=a727600194' target=_blank style='color:#2F92EE;'>#Disord#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6001, encryptionId=a727600194, topicName=Disord)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aad0444, createdName=cmsvly, createdTime=Sat Oct 16 20:07:51 CST 2021, time=2021-10-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2013682, encodeId=2d2b2013682fa, content=<a href='/topic/show?id=7d69598468' target=_blank style='color:#2F92EE;'>#Dis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5984, encryptionId=7d69598468, topicName=Dis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Mon Nov 08 20:07:51 CST 2021, time=2021-11-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1309253, encodeId=640f1309253c1, content=<a href='/topic/show?id=8dbb29086c6' target=_blank style='color:#2F92EE;'>#免疫特征#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=29086, encryptionId=8dbb29086c6, topicName=免疫特征)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e080359, createdName=surilei, createdTime=Mon Aug 09 20:07:51 CST 2021, time=2021-08-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1578576, encodeId=113f15e85760d, content=<a href='/topic/show?id=fd724282021' target=_blank style='color:#2F92EE;'>#外周血#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42820, encryptionId=fd724282021, topicName=外周血)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a31916414168, createdName=ms3994565386320060, createdTime=Mon Aug 09 20:07:51 CST 2021, time=2021-08-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1006100, encodeId=f5451006100cb, content=有收获, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=05885564664, createdName=ms3000000120045871, createdTime=Sun Aug 08 19:06:08 CST 2021, time=2021-08-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1005989, encodeId=93111005989b1, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201210/017ce76ad1014a7ab78fda1719777146/e1909743852a42449a457ef64bb5bfe8.jpg, createdBy=26641794232, createdName=ms812711744394816, createdTime=Sun Aug 08 10:55:25 CST 2021, time=2021-08-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1005951, encodeId=b9c2100595128, content=顶, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1f685566957, createdName=jyq1990, createdTime=Sun Aug 08 08:42:41 CST 2021, time=2021-08-08, status=1, ipAttribution=)]
    2021-08-08 ms3000000120045871

    有收获

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=1784450, encodeId=ef211e84450c9, content=<a href='/topic/show?id=a727600194' target=_blank style='color:#2F92EE;'>#Disord#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6001, encryptionId=a727600194, topicName=Disord)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aad0444, createdName=cmsvly, createdTime=Sat Oct 16 20:07:51 CST 2021, time=2021-10-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2013682, encodeId=2d2b2013682fa, content=<a href='/topic/show?id=7d69598468' target=_blank style='color:#2F92EE;'>#Dis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5984, encryptionId=7d69598468, topicName=Dis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Mon Nov 08 20:07:51 CST 2021, time=2021-11-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1309253, encodeId=640f1309253c1, content=<a href='/topic/show?id=8dbb29086c6' target=_blank style='color:#2F92EE;'>#免疫特征#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=29086, encryptionId=8dbb29086c6, topicName=免疫特征)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e080359, createdName=surilei, createdTime=Mon Aug 09 20:07:51 CST 2021, time=2021-08-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1578576, encodeId=113f15e85760d, content=<a href='/topic/show?id=fd724282021' target=_blank style='color:#2F92EE;'>#外周血#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42820, encryptionId=fd724282021, topicName=外周血)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a31916414168, createdName=ms3994565386320060, createdTime=Mon Aug 09 20:07:51 CST 2021, time=2021-08-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1006100, encodeId=f5451006100cb, content=有收获, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=05885564664, createdName=ms3000000120045871, createdTime=Sun Aug 08 19:06:08 CST 2021, time=2021-08-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1005989, encodeId=93111005989b1, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201210/017ce76ad1014a7ab78fda1719777146/e1909743852a42449a457ef64bb5bfe8.jpg, createdBy=26641794232, createdName=ms812711744394816, createdTime=Sun Aug 08 10:55:25 CST 2021, time=2021-08-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1005951, encodeId=b9c2100595128, content=顶, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1f685566957, createdName=jyq1990, createdTime=Sun Aug 08 08:42:41 CST 2021, time=2021-08-08, status=1, ipAttribution=)]
    2021-08-08 ms812711744394816

    学习了

    0

  7. [GetPortalCommentsPageByObjectIdResponse(id=1784450, encodeId=ef211e84450c9, content=<a href='/topic/show?id=a727600194' target=_blank style='color:#2F92EE;'>#Disord#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6001, encryptionId=a727600194, topicName=Disord)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aad0444, createdName=cmsvly, createdTime=Sat Oct 16 20:07:51 CST 2021, time=2021-10-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2013682, encodeId=2d2b2013682fa, content=<a href='/topic/show?id=7d69598468' target=_blank style='color:#2F92EE;'>#Dis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5984, encryptionId=7d69598468, topicName=Dis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Mon Nov 08 20:07:51 CST 2021, time=2021-11-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1309253, encodeId=640f1309253c1, content=<a href='/topic/show?id=8dbb29086c6' target=_blank style='color:#2F92EE;'>#免疫特征#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=29086, encryptionId=8dbb29086c6, topicName=免疫特征)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e080359, createdName=surilei, createdTime=Mon Aug 09 20:07:51 CST 2021, time=2021-08-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1578576, encodeId=113f15e85760d, content=<a href='/topic/show?id=fd724282021' target=_blank style='color:#2F92EE;'>#外周血#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42820, encryptionId=fd724282021, topicName=外周血)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a31916414168, createdName=ms3994565386320060, createdTime=Mon Aug 09 20:07:51 CST 2021, time=2021-08-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1006100, encodeId=f5451006100cb, content=有收获, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=05885564664, createdName=ms3000000120045871, createdTime=Sun Aug 08 19:06:08 CST 2021, time=2021-08-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1005989, encodeId=93111005989b1, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201210/017ce76ad1014a7ab78fda1719777146/e1909743852a42449a457ef64bb5bfe8.jpg, createdBy=26641794232, createdName=ms812711744394816, createdTime=Sun Aug 08 10:55:25 CST 2021, time=2021-08-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1005951, encodeId=b9c2100595128, content=顶, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1f685566957, createdName=jyq1990, createdTime=Sun Aug 08 08:42:41 CST 2021, time=2021-08-08, status=1, ipAttribution=)]
    2021-08-08 jyq1990

    0

相关资讯

Mov Disord:血液中的细胞外囊泡,可有效诊断帕金森

德国波恩大学研究团队发现血浆胞外囊泡中的α-synuclein浓度,可作为PD的潜在诊断生物标志物。

Mov Disord-新型标记物: 鞘氨醇-1-磷酸酯可预测帕金森的病情进展

新型标记物: 鞘氨醇-1-磷酸酯可预测帕金森的病情进展

Mov Disord:认知行为疗法,有助于减轻帕金森患者的焦虑状态?

认知行为疗法,有助于减轻帕金森患者的焦虑状态?

Mov Disord:神经黑色素变化,和帕金森病的恶化高度相关

神经黑色素变化,和帕金森病的恶化高度相关

Mov Disord:双侧卵巢切除术后,女性更容易患帕金森病

双侧卵巢切除术后,女性更容易患帕金森病。

Mov Disord:早期帕金森患者,脑脊液的神经递质如何变化?

早期帕金森患者,脑脊液的神经递质如何变化?

拓展阅读

好文推荐 | 北京地区帕金森病相关认知域评估量表的划界值研究

构建北京地区PD相关认知域评估量表的划界分常模并进行最佳划界值的筛选,为国内临床医生诊断PD-MCI提供可靠的评估标准。

IVD前沿丨帕金森病(PD)早期诊断新型生物标志物

这些结果强调了血浆中含有miR-44438的EV作为α-突触核蛋白病早期检测和进展监测的生物标志物的潜力。

帕金森病获治疗重大突破!每周一次,长效微球制剂「罗替高汀微球」在华落地!

注射用罗替高汀微球是全球首个治疗帕金森病的长效缓释微球制剂,也是目前更符合“持续多巴胺能刺激(CDS)”理念的周制剂。

Nature Genetics:揭示帕金森病的幕后推手:RAB32基因新变异的发现

这项研究也证明了家族性病例的采集和大量对照组结合使用在识别低频变异中的有效性,这对于PD以及其他复杂疾病的遗传研究具有重要意义。

好文推荐 | 中国人群帕金森病轻度认知障碍综合认知域评估量表的筛选及诊断效度分析

使用推荐的临界值后可以更好将PD-MCI进行亚型分析,便于临床观察各亚型PD-MCI转归及临床特异性,具有一定临床意义。

走路越来越慢,害怕跌倒是脑梗?帕金森?帕金森综合征?还是帕金森叠加综合征?

帕金森综合征是由于中脑部发生病变,正常情况下,黑质神经元的神经细胞产生多巴胺,从而对大脑的运动功能进行调节。如果黑质神经元的神经细胞受到了破坏,无法产生多巴胺,那么就会导致帕金森综合征的出现。

2024 NICE 诊断指南:帕金森病远程监测设备 [DG51]

英国国家卫生与临床优化研究所(NICE,National Institute for Health and Clinical Excellence) · 2024-01-25

2023 NICE 技术鉴定指南:左旋多巴/卡比多巴组合治疗伴有运动症状的晚期帕金森病[TA934]

英国国家卫生与临床优化研究所(NICE,National Institute for Health and Clinical Excellence) · 2023-11-29

帕金森病患者睡眠障碍评估与护理干预的最佳证据总结

浙江中医药大学护理学院 · 2023-08-10